Todd C. Brady - 16 Dec 2025 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Role: Director
Signature: /s/ Matthew J. D'Onofrio, Attorney-in-fact for Todd C. Brady
Issuer symbol: EVOK
Transactions as of: 16 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 17 Dec 2025, 16:00:06 UTC
Previous filing: 22 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Brady Todd C	Director	C/O EVOKE PHARMA, INC., 420 STEVENS AVENUE, SUITE 230, SOLANA BEACH	/s/ Matthew J. D'Onofrio, Attorney-in-fact for Todd C. Brady	17 Dec 2025	0001579179

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EVOK	Common Stock	Disposition pursuant to a tender of shares in a change of control transaction		-27	-100%		0	16 Dec 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVOK	Stock Option (Right to Buy)	Disposed to Issuer	-1,218	-100%	17 Dec 2025	Common Stock	1,218	$5.41	Direct	F2
transaction	EVOK	Stock Option (Right to Buy)	Disposed to Issuer	-5,833	-100%	17 Dec 2025	Common Stock	5,833	$4.45	Direct	F2
transaction	EVOK	Stock Option (Right to Buy)	Disposed to Issuer	-1,187	-100%	17 Dec 2025	Common Stock	1,187	$3.45	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Todd C. Brady is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the "Offer Price").
F2	After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.

Content

On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the "Offer Price").

After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.